Table 1.

Patient baseline characteristics in relation to the results of indication biopsies

CharacteristicAll Patientsv (n=885)C4d in PTCsaABMR Featuresb
Yes (n=154)No (n=671)P ValueYes (n=380)No (n=494)P Value
Recipient age (yr)52 (41–62)50 (40–60)52 (41–62)0.0848 (38–58)55 (44–64)<0.001
Donor age (yr)50 (39–60)46 (36–59)51 (40–60)0.00350 (39–59)51 (40–60)0.10
Deceased donor transplants783 (89)140 (91)587 (88)0.25335 (88)438 (88)0.82
Prior allograft161(18)53 (34)100 (15)<0.001105 (27)55 (11)<0.001
≥10% current CDC-PRA191 (22)65 (42)120 (18)<0.001113 (30)78 (16)<0.001
HLA mismatch (A, B, DR)3 (2–4)3 (2–4)3 (2–4)0.303 (2–4)3 (2–4)0.001
Cold ischemia time (h)13 (8–19)13 (9–19)13 (8–19)0.1213 (8–19)12 (8–18)0.21
Initial immunosuppressive therapy
 Cyclosporine656 (74)127 (83)484 (72)0.008297 (78)351 (71)0.02
 Tacrolimus148 (17)20 (13)118 (18)0.1758 (15)89 (18)0.27
 IL-2 receptor antibody161 (18)19 (12)130 (19)0.0551 (13)108 (22)0.001
 Depleting antilymphocyte antibody122 (14)46 (30)68 (10)<0.00167 (18)53 (11)0.004
 Peritransplant IA66 (8)30 (20)33 (5)<0.00147 (12)19 (4)<0.001
 mTOR inhibitor with or without CNI99 (11)8 (5)82 (12)0.0133 (9)58 (12)0.15
  • Values are median (interquartile range) or number (percentage). For comparative analysis, Fisher exact and Mann–Whitney U tests were applied. CDC-PRA, complement-dependent cytotoxicity panel-reactive antibody; mTOR, mammalian target of rapamycin; IA, immunoadsorption; CNI, calcineurin inhibitor; PTCs, peritubular capillaries; ABMR, antibody-mediated rejection.

  • a C4d staining results were available for 825 of the 885 included study patients. Patients with C4d scores > 0 were categorized as C4d+.

  • b Biopsy material for a histomorphologic evaluation of ABMR-typical lesions (g, ptc, cg, v3 lesions, capillary microthrombi) was available for 874 of the 885 included study patients.